The effect of intravitreal cidofovir injection on end-stage glaucoma in dogs: a retrospective study of 153 eyes.

IF 1.6 2区 农林科学 Q2 VETERINARY SCIENCES
Hyelin Kim, Seonmi Kang, Dajeong Jeong, Junyeong Ahn, Kangmoon Seo
{"title":"The effect of intravitreal cidofovir injection on end-stage glaucoma in dogs: a retrospective study of 153 eyes.","authors":"Hyelin Kim, Seonmi Kang, Dajeong Jeong, Junyeong Ahn, Kangmoon Seo","doi":"10.2460/javma.24.03.0199","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term efficacy, prognostic factors, and complications of intravitreal cidofovir injection in dogs with end-stage glaucoma.</p><p><strong>Animals: </strong>130 client-owned dogs.</p><p><strong>Methods: </strong>Medical records of dogs that underwent intravitreal cidofovir injections were reviewed. A minimum follow-up period of 6 months was required as the inclusion criterion. Signalment, type of glaucoma, preinjection intraocular pressure (IOP), types of applied glaucoma eye drop, coexisting ocular diseases, outcomes, and complications were recorded. Success was defined as IOP of ≤ 25 mm Hg at the 2-week recheck that remained to the 6-month recheck.</p><p><strong>Results: </strong>The overall success rate of intravitreal cidofovir injection was 91.5% (140/153). The success rate of a single injection was 69.3% (106/153), of a second injection was 59.5% (25/42), of a third injection was 42.9% (6/14), of a fourth injection was 33.3% (2/6), and of a fifth injection was 50.0% (1/2). Intraocular pressures at 6 months after injection were relatively higher when the injection was repeated, fewer types of glaucoma eye drop were applied prior to the injection, and cataract stages were advanced at the time of injection (P < .05). The most common complications were phthisis bulbi (42.5%), cataract progression (30.1%), and intraocular hemorrhage (16.3%). Six eyes were enucleated, and 3 were enucleated due to corneal perforation.</p><p><strong>Clinical relevance: </strong>Intravitreal cidofovir injection had a high long-term success rate in lowering IOP in dogs with end-stage glaucoma.</p>","PeriodicalId":14658,"journal":{"name":"Javma-journal of The American Veterinary Medical Association","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Javma-journal of The American Veterinary Medical Association","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/javma.24.03.0199","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the long-term efficacy, prognostic factors, and complications of intravitreal cidofovir injection in dogs with end-stage glaucoma.

Animals: 130 client-owned dogs.

Methods: Medical records of dogs that underwent intravitreal cidofovir injections were reviewed. A minimum follow-up period of 6 months was required as the inclusion criterion. Signalment, type of glaucoma, preinjection intraocular pressure (IOP), types of applied glaucoma eye drop, coexisting ocular diseases, outcomes, and complications were recorded. Success was defined as IOP of ≤ 25 mm Hg at the 2-week recheck that remained to the 6-month recheck.

Results: The overall success rate of intravitreal cidofovir injection was 91.5% (140/153). The success rate of a single injection was 69.3% (106/153), of a second injection was 59.5% (25/42), of a third injection was 42.9% (6/14), of a fourth injection was 33.3% (2/6), and of a fifth injection was 50.0% (1/2). Intraocular pressures at 6 months after injection were relatively higher when the injection was repeated, fewer types of glaucoma eye drop were applied prior to the injection, and cataract stages were advanced at the time of injection (P < .05). The most common complications were phthisis bulbi (42.5%), cataract progression (30.1%), and intraocular hemorrhage (16.3%). Six eyes were enucleated, and 3 were enucleated due to corneal perforation.

Clinical relevance: Intravitreal cidofovir injection had a high long-term success rate in lowering IOP in dogs with end-stage glaucoma.

玻璃体内注射西多福韦对犬终末期青光眼的影响:对 153 只眼睛的回顾性研究。
目的评估对患有终末期青光眼的狗进行玻璃体内注射西多福韦的长期疗效、预后因素和并发症:方法:对接受过玻璃体内西多福韦注射的狗的病历进行审查。纳入标准是至少随访 6 个月。记录信号、青光眼类型、注射前眼压(IOP)、使用的青光眼眼药水类型、并存的眼部疾病、疗效和并发症。2周复查时眼压低于25毫米汞柱并保持到6个月复查时为成功:结果:玻璃体内注射西多福韦的总成功率为91.5%(140/153)。单次注射成功率为 69.3%(106/153),第二次注射成功率为 59.5%(25/42),第三次注射成功率为 42.9%(6/14),第四次注射成功率为 33.3%(2/6),第五次注射成功率为 50.0%(1/2)。重复注射时,注射后 6 个月的眼压相对较高,注射前使用的青光眼眼药水种类较少,注射时白内障分期较晚(P < .05)。最常见的并发症是球结膜炎(42.5%)、白内障进展(30.1%)和眼内出血(16.3%)。6只眼睛被摘除眼球,3只眼睛因角膜穿孔而被摘除眼球:临床意义:玻璃体内注射西多福韦在降低终末期青光眼患犬的眼压方面具有很高的长期成功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
15.80%
发文量
539
审稿时长
6-16 weeks
期刊介绍: Published twice monthly, this peer-reviewed, general scientific journal provides reports of clinical research, feature articles and regular columns of interest to veterinarians in private and public practice. The News and Classified Ad sections are posted online 10 days to two weeks before they are delivered in print.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信